Limits...
Effects of Combined Soy Isoflavone Extract and Docetaxel Treatment on Murine 4T1 Breast Tumor Model.

Hejazi E, Nasrollahzadeh J, Fatemi R, Barzegar-Yar Mohamadi L, Saliminejad K, Amiri Z, Kimiagar M, Houshyari M, Tavakoli M, Idali F - Avicenna J Med Biotechnol (2015 Jan-Mar)

Bottom Line: In DOCE+SIE group, diet consumption was significantly higher than DOCE group.The mRNA expression was not significantly different among groups.The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT

Background: Emergence of drug resistance has brought major problems in chemotherapy. Using nutrients in combination with chemotherapy could be beneficial for improvement of sensitivity of tumors to drug resistance. Soybean-derived isoflavones have been suggested as chemopreventive agents for certain types of cancer, particularly breast cancer. In this study, the synergistic effects of soy isoflavone extract in combination with docetaxel in murine 4T1 breast tumor model were investigated.

Methods: In this study, mice were divided into 4 groups (15 mice per group) of control, the dietary Soy Isoflavone Extract (SIE, 100 mg/kg diet), the Docetaxel (DOCE, 10 mg/kg) injection and the combination of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE). After 3 injections of docetaxel (once a week), 7 mice were sacrificed to analyze MKI67 gene and protein expressions and the rest were monitored for diet consumption, tumor growth and survival rates.

Results: In DOCE+SIE group, diet consumption was significantly higher than DOCE group. While lifespan showed a trend towards improvement in DOCE+SIE group, no significant difference was observed among the 4 studied groups. Tumor volume was not significantly affected in treated groups. A lower but not significant MKI67 protein expression was detected in western blot in DOCE+SIE group. The mRNA expression was not significantly different among groups.

Conclusion: The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

No MeSH data available.


Related in: MedlinePlus

Effect of soy isoflavone extract on tumor volume of 4T1 mice mammary fat pad tumors (15 per group). The means of tumor volume in control, SIE, DOCE and DOCE+SIE groups were 221± 111, 235±114, 166±79 and 148±74 mm3, respectively. No significant differences were detected between groups. Control group received AIN 93M diet, the dietary soy isoflavones extract (SIE) group received AIN 93 M diet+100 mg SIE, the intravenous docetaxel injection (DOCE) group received 10 mg/kg DOCE and the combination group received soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4388885&req=5

Figure 0003: Effect of soy isoflavone extract on tumor volume of 4T1 mice mammary fat pad tumors (15 per group). The means of tumor volume in control, SIE, DOCE and DOCE+SIE groups were 221± 111, 235±114, 166±79 and 148±74 mm3, respectively. No significant differences were detected between groups. Control group received AIN 93M diet, the dietary soy isoflavones extract (SIE) group received AIN 93 M diet+100 mg SIE, the intravenous docetaxel injection (DOCE) group received 10 mg/kg DOCE and the combination group received soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE).

Mentions: Figure 3 shows that there were no significant differences between tumor volumes of the groups. A slight decrease in tumor volume was seen in DOCE+SIE group compared to DOCE group. Soy isoflavone extract exerted no effect on tumor volume in SIE group compared to the control group. The means of tumor volume in control, SIE, DOCE and DOCE+SIE groups were 221±111, 235±114, 166±79 and 148±74 mm3, respectively.


Effects of Combined Soy Isoflavone Extract and Docetaxel Treatment on Murine 4T1 Breast Tumor Model.

Hejazi E, Nasrollahzadeh J, Fatemi R, Barzegar-Yar Mohamadi L, Saliminejad K, Amiri Z, Kimiagar M, Houshyari M, Tavakoli M, Idali F - Avicenna J Med Biotechnol (2015 Jan-Mar)

Effect of soy isoflavone extract on tumor volume of 4T1 mice mammary fat pad tumors (15 per group). The means of tumor volume in control, SIE, DOCE and DOCE+SIE groups were 221± 111, 235±114, 166±79 and 148±74 mm3, respectively. No significant differences were detected between groups. Control group received AIN 93M diet, the dietary soy isoflavones extract (SIE) group received AIN 93 M diet+100 mg SIE, the intravenous docetaxel injection (DOCE) group received 10 mg/kg DOCE and the combination group received soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4388885&req=5

Figure 0003: Effect of soy isoflavone extract on tumor volume of 4T1 mice mammary fat pad tumors (15 per group). The means of tumor volume in control, SIE, DOCE and DOCE+SIE groups were 221± 111, 235±114, 166±79 and 148±74 mm3, respectively. No significant differences were detected between groups. Control group received AIN 93M diet, the dietary soy isoflavones extract (SIE) group received AIN 93 M diet+100 mg SIE, the intravenous docetaxel injection (DOCE) group received 10 mg/kg DOCE and the combination group received soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE).
Mentions: Figure 3 shows that there were no significant differences between tumor volumes of the groups. A slight decrease in tumor volume was seen in DOCE+SIE group compared to DOCE group. Soy isoflavone extract exerted no effect on tumor volume in SIE group compared to the control group. The means of tumor volume in control, SIE, DOCE and DOCE+SIE groups were 221±111, 235±114, 166±79 and 148±74 mm3, respectively.

Bottom Line: In DOCE+SIE group, diet consumption was significantly higher than DOCE group.The mRNA expression was not significantly different among groups.The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT

Background: Emergence of drug resistance has brought major problems in chemotherapy. Using nutrients in combination with chemotherapy could be beneficial for improvement of sensitivity of tumors to drug resistance. Soybean-derived isoflavones have been suggested as chemopreventive agents for certain types of cancer, particularly breast cancer. In this study, the synergistic effects of soy isoflavone extract in combination with docetaxel in murine 4T1 breast tumor model were investigated.

Methods: In this study, mice were divided into 4 groups (15 mice per group) of control, the dietary Soy Isoflavone Extract (SIE, 100 mg/kg diet), the Docetaxel (DOCE, 10 mg/kg) injection and the combination of dietary soy isoflavone extract and intravenous docetaxel injection (DOCE+SIE). After 3 injections of docetaxel (once a week), 7 mice were sacrificed to analyze MKI67 gene and protein expressions and the rest were monitored for diet consumption, tumor growth and survival rates.

Results: In DOCE+SIE group, diet consumption was significantly higher than DOCE group. While lifespan showed a trend towards improvement in DOCE+SIE group, no significant difference was observed among the 4 studied groups. Tumor volume was not significantly affected in treated groups. A lower but not significant MKI67 protein expression was detected in western blot in DOCE+SIE group. The mRNA expression was not significantly different among groups.

Conclusion: The results suggest that the combination of soy isoflavone as an adjunct to docetaxel chemotherapy can be effective in improving diet consumption in breast cancer.

No MeSH data available.


Related in: MedlinePlus